Glucagon-like peptide-1, glucose homeostasis and diabetes.

Research output: Contribution to journalJournal articleResearchpeer-review

Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor beta-cell function in patients with type-2 diabetes mellitus. However, at supraphysiological doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. The pathophysiological basis the clinical use of these therapeutics is reviewed here.
Original languageEnglish
JournalTrends in Molecular Medicine
Issue number4
Pages (from-to)161-8
Number of pages8
Publication statusPublished - 2008

Bibliographical note

Keywords: Diabetes Mellitus; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans

ID: 8416785